Abiopharma

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

The Joint Corp. Reports Second Quarter 2025 Financial Results

AVITA Medical Reports Second Quarter 2025 Financial Results, Updates Full-Year Guidance, and Highlights Continued Clinical Innovation

New Form 10-Q - ARROWHEAD PHARMACEUTICALS, INC. Filed: 2025-08-07 AccNo: 0001628280-25-038858 Size: 9 MB

New Form 10-Q - STERIS plc Filed: 2025-08-07 AccNo: 0001757898-25-000008 Size: 8 MB

BioLife Solutions Reports Second Quarter 2025 Financial Results

Owlet Reports Second Quarter 2025 Financial Results; Increases Full Year 2025 Guidance; Announces CEO Transition Plan

Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

10x Genomics Reports Second Quarter 2025 Financial Results

New Form 8-K - DYNAVAX TECHNOLOGIES CORP Filed: 2025-08-07 AccNo: 0001029142-25-000115 Size: 310 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - Stereotaxis, Inc. Filed: 2025-08-07 AccNo: 0001641172-25-022580 Size: 375 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

10x Genomics - 10x Genomics to Acquire Scale Biosciences

New Form 8-K - aTYR PHARMA INC Filed: 2025-08-07 AccNo: 0001339970-25-000007 Size: 443 KB Item 2.06: Material Impairments Item 9.01: Financial Statements and Exhibits

10x Genomics to Acquire Scale Biosciences